drugset / Trial / NCT02851004
Special Combination of BBI608 and Pembrolizumab
NaSingle-groupOpen-labelTreatment
Summary
the efficacy and safety of BBI608 in combination with pembrolizumab
Timeline
- Start
- 2016-10
- Primary completion
- 2020-02-03
- Completion
- 2021-08-23
Outcome
Outcome not reported
Stopped (Enrollment): “On the request of the investigational drug provider. No subjects were newly enrolled in the additional cohort as they were preparing to resume enrollment in the additional cohort. Currently, it is preparing the creation of clinical study report.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Napabucasin | Small molecule | 240 mg | Oral |
| Subject | Napabucasin | Small molecule | 480 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |